SCHEMBL23980864

SCHEMBL23980864

O=C(COc1c(Br)cccc1[N+](=O)[O-])c1ccc(Cl)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
KDM4E B2RXH2 2/20 0.38
PDE7A Q13946 2/20 0.38
PDE7B Q9NP56 2/20 0.38
G6PD P11413 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
HPGD P15428 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C19 P33261 2/20 0.38
RAB9A P51151 4/20 0.37
NPC1 O15118 3/20 0.37
HSPB1 P04792 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30217405 1.00 MAPT (0.44) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL30217421 0.89 RAB9A (0.45) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL23980856 0.89 RAB9A (0.45) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL29149922 0.83 KMT2A (0.43) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL23980879 0.81 PTGDR2 (0.40) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL30217445 0.81 PTGDR2 (0.40) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL29924435 0.78 LMNA (0.44) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL29150166 0.78 LMNA (0.44) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL26304940 0.77 RAB9A (0.37) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL29924275 0.76 LMNA (0.49) MAPTMEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4143183-B1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC (US) 2025-10-22 EP disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
CN-115667250-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-01-31 CN disclosed
WO-2021219019-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR MAPT 3873/4885MEN1 517/4885KMT2A 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.